Lawrence Y Agodoa1, Mildred E Francis, Paul W Eggers. 1. Division of Kidney, Urologic, and Hematologic Disorders, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892-5458, USA. agodoal@extra.niddk.nih.gov
Abstract
BACKGROUND: Prolonged analgesic consumption may adversely affect kidney function. The relation of long-term analgesic use to markers of decreased kidney function has not been investigated in the general population. DESIGN: Cross-sectional analysis. SETTING: National Health and Nutrition Examination Survey conducted in 1999-2002. PARTICIPANTS: Noninstitutionalized residents at least 20 years old (n = 8,057, representing 177.8 million adults). PREDICTORS: Ever intake of an analgesic every day for at least a month defined habitual analgesic use, classified by product (aspirin, acetaminophen, ibuprofen, and selected prescription drugs) and years of use (<1, 1 to 5, and >5 years). OUTCOMES: Albuminuria in random urine (albumin-creatinine ratio >or= 30 mg/g; n = 1,088) and reduced estimated glomerular filtration rate (eGFR; <60 mL/min/1.73 m(2), n = 852) using the Modification of Diet in Renal Disease Study equation and the composite of either. MEASUREMENTS: Age-standardized prevalence in habitual analgesic users and non-habitual analgesic users and multivariable-adjusted odds ratios (ORs). RESULTS: In US adults, 23.7% (95% confidence interval [CI], 21.7 to 25.6) reported habitual analgesic use. Multivariable-adjusted ORs for reduced eGFR prevalence in adults with habitual analgesic use of acetaminophen only, ibuprofen only, and aspirin only were 1.03 (95% CI, 0.6 to 1.7), 1.21 (95% CI, 0.7 to 2.1), and 0.95 (95% CI, 0.7 to 1.2) compared with non-habitual analgesic use, respectively. Corresponding ORs for prevalent albuminuria were 0.93 (95% CI, 0.7 to 1.3), 0.65 (95% CI, 0.4 to 1.2), and 0.86 (95% CI, 0.6 to 1.2). Association measures had intermediate levels for the composite marker of decreased kidney function and were not significant. No association between prevalent outcomes and habitual analgesic exposure duration of 5 years or longer or multiple product habitual analgesic consumption was observed. LIMITATIONS: Reliability of self-reported analgesic use behavior was not assessed. CONCLUSIONS: Habitual analgesic use of single or multiple products was not associated with increased prevalence of albuminuria or reduced eGFR.
BACKGROUND: Prolonged analgesic consumption may adversely affect kidney function. The relation of long-term analgesic use to markers of decreased kidney function has not been investigated in the general population. DESIGN: Cross-sectional analysis. SETTING: National Health and Nutrition Examination Survey conducted in 1999-2002. PARTICIPANTS: Noninstitutionalized residents at least 20 years old (n = 8,057, representing 177.8 million adults). PREDICTORS: Ever intake of an analgesic every day for at least a month defined habitual analgesic use, classified by product (aspirin, acetaminophen, ibuprofen, and selected prescription drugs) and years of use (<1, 1 to 5, and >5 years). OUTCOMES: Albuminuria in random urine (albumin-creatinine ratio >or= 30 mg/g; n = 1,088) and reduced estimated glomerular filtration rate (eGFR; <60 mL/min/1.73 m(2), n = 852) using the Modification of Diet in Renal Disease Study equation and the composite of either. MEASUREMENTS: Age-standardized prevalence in habitual analgesic users and non-habitual analgesic users and multivariable-adjusted odds ratios (ORs). RESULTS: In US adults, 23.7% (95% confidence interval [CI], 21.7 to 25.6) reported habitual analgesic use. Multivariable-adjusted ORs for reduced eGFR prevalence in adults with habitual analgesic use of acetaminophen only, ibuprofen only, and aspirin only were 1.03 (95% CI, 0.6 to 1.7), 1.21 (95% CI, 0.7 to 2.1), and 0.95 (95% CI, 0.7 to 1.2) compared with non-habitual analgesic use, respectively. Corresponding ORs for prevalent albuminuria were 0.93 (95% CI, 0.7 to 1.3), 0.65 (95% CI, 0.4 to 1.2), and 0.86 (95% CI, 0.6 to 1.2). Association measures had intermediate levels for the composite marker of decreased kidney function and were not significant. No association between prevalent outcomes and habitual analgesic exposure duration of 5 years or longer or multiple product habitual analgesic consumption was observed. LIMITATIONS: Reliability of self-reported analgesic use behavior was not assessed. CONCLUSIONS: Habitual analgesic use of single or multiple products was not associated with increased prevalence of albuminuria or reduced eGFR.
Authors: Krupa Patel; Clarissa Diamantidis; Min Zhan; Van Doren Hsu; Loreen D Walker; James Gardner; Matthew R Weir; Jeffrey C Fink Journal: Am J Nephrol Date: 2012-06-13 Impact factor: 3.754
Authors: Yun Han; Rajesh Balkrishnan; Richard A Hirth; David W Hutton; Kevin He; Diane E Steffick; Rajiv Saran Journal: JAMA Netw Open Date: 2020-09-01
Authors: Daria Golosova; Oleg Palygin; Ruslan Bohovyk; Christine A Klemens; Vladislav Levchenko; Denisha R Spires; Elena Isaeva; Ashraf El-Meanawy; Alexander Staruschenko Journal: Life Sci Alliance Date: 2020-10-12